Table 1. Characteristics of SLE patients and HCs in the two studies.
| Study: Flow cytometric T-cell analysis |
Study: Cytokine quantification by luminex |
||
|---|---|---|---|
| SLE patients cohort 1 | SLE patients cohort 2 | ||
| No. of individuals | 17 | 17 | |
| Mean age (years) (range) | 40.7 (21–81) | 42,6 (23–61) | |
| Females | 94% | 100% | |
| Disease manifestations: | |||
| Nephritis | 29% | 12% | |
| Vasculitis | 0% | 0% | |
| Arthritis | 29% | 6% | |
| Rash | 18% | 18% | |
| Alopecia | 0% | 0% | |
| Myositis | 0% | 0% | |
| Mucosal ulcers | 0% | 0% | |
| Serositis | 6% | 6% | |
| Leucopenia | 12% | 0% | |
| Thrombocytopenia | 18% | 0% | |
| Visual disturbance | 0% | 0% | |
| Fever | 18% | 0% | |
| Mean SLEDAI score (range) | 6.7 (0–22) | 3.2 (0–12) | |
| dsDNA antibody positive | 47% | 65% | |
| Rheumafactor positive | |||
| IgA | 12% | 29% | |
| IgM | 0% | 24% | |
| Low C3 or C4 level | 71% | 35% | |
| Mean C-reactive protein (mg/L) (range) | 5.7 (1–22) | 6.4 (1–38) | |
| Medication: | |||
| Prednisolone (median dose, mg) | 65% (5) | 24% (0) | |
| Azathioprine (median dose, mg) | 29% (0) | 18% (0) | |
| Mycophenolate mofetil (median dose, mg) | 24% (0) | 18% (0) | |
| Methotrexate (median dose, mg) | 12% (0) | 6% (0) | |
| Hydroxychloroquine (median dose, mg) | 59% (200) | 47% (0) | |
| Anticoagulant | 35% | 47% | |
| Antihypertension | 24% | 35% | |
| HCs cohort 1 | HCs cohort 2 | ||
| No. of individuals | 17 | 17 | |
| Mean age (years) (range) | 37.3 (25–59) | 42.9 (28–64) | |
| Females | 94% | 100% | |